← Back to Clinical Trials
Recruiting NCT07554755

NCT07554755 TIS for NSSI in Adolescent Depression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07554755
Status Recruiting
Phase
Sponsor The Second Hospital of Anhui Medical University
Condition Temporal Interference Stimulation
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2026-04-30
Primary Completion 2026-10-30

Eligibility & Interventions

Sex All sexes
Min Age 12 Years
Max Age 22 Years
Study Type INTERVENTIONAL
Interventions
Active Temporal Interference Stimulation (TIS)Sham Temporal Interference Stimulation (TIS)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2026-04-30 with a primary completion date of 2026-10-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Temporal Interference Stimulation (TIS) has been successfully used to help patients with depression. However, its role in alleviating self injuries remained uncertain. This trial will compare the effectiveness of TIS to a placebo control on non-suicidal self injury (NSSI) in patients with major depressive disorder(MDD).

Eligibility Criteria

Inclusion Criteria: 1. Meet the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders 5th Edition) diagnostic criteria for major depressive disorder. 2. Patients aged 12-22 years with at least one guardian to monitor them for 3 months 3. HAMD-17 Total score ≥18 4. Patients who had two or more non-suicidal self-injury behaviors meeting the 5.DSM-5 diagnostic criteria in the 2 weeks before admission (NSSI behavior of more than 5 days in the past year) 6.Obtain informed consent from patients and guardians \- Exclusion Criteria: 1. Substance abusers such as psychoactive drugs or alcohol. 2. Severe physical disability and unable to complete follow-up. 3. Comorbid other major mental illnesses that meet the DSM-5 criteria, such as bipolar disorder, schizophrenia, mental retardation, dementia, severe cognitive impairment, attention deficit hyperactivity disorder, etc. 4. Suffering from any severe physical disease, neurological disease, traumatic brain injury, etc, that affects the structure or function of the brain in the lifetime. Unable to read, understand and complete the assessment or to cooperate with the investigators. 5. Any implants covering a pacemaker, metallic or magnetic objects in the body, or other conditions not suitable for TIS. 6. Those who have received systematic psychotherapy (interpersonal relationship therapy, dynamic therapy, cognitive behavioral therapy) or TMS within 3 months before baseline. 7. Other examination abnormalities considered to be inappropriate by investigators. \-

Contact & Investigator

Central Contact

Yanghua Tian, PhD

✉ tianyh@ahmu.edu.cn

📞 +86-13955188448

Frequently Asked Questions

Who can join the NCT07554755 clinical trial?

This trial is open to participants of all sexes, aged 12 Years or older, up to 22 Years, studying Temporal Interference Stimulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07554755 currently recruiting?

Yes, NCT07554755 is actively recruiting participants. Contact the research team at tianyh@ahmu.edu.cn for enrollment information.

Where is the NCT07554755 trial being conducted?

This trial is being conducted at Hefei, China.

Who is sponsoring the NCT07554755 clinical trial?

NCT07554755 is sponsored by The Second Hospital of Anhui Medical University. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology